Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Personalis Inc (NQ: PSNL )

2.195 -0.345 (-13.60%)
Streaming Delayed Price Updated: 2:57 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 354,864
Open 2.560
Bid (Size) 2.190 (2)
Ask (Size) 2.200 (2)
Prev. Close 2.540
Today's Range 2.185 - 2.590
52wk Range 1.730 - 5.575
Shares Outstanding 46,783,757
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
From Personalis, Inc.
Via Business Wire
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
From Personalis, Inc.
Via Business Wire

Performance

YTD
+9.18%
+9.18%
1 Month
-3.33%
-3.33%
3 Month
-27.33%
-27.33%
6 Month
-9.69%
-9.69%
1 Year
-37.30%
-37.30%

More News

Read More
Analyst Ratings for Personalis
Via Benzinga
Recap: Personalis Q1 Earnings
Via Benzinga
Personalis Reports First Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis's Return On Capital Employed Insights
Via Benzinga
Earnings Outlook For Personalis
Via Benzinga
Cancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its Workforce
Via Benzinga
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
From Personalis, Inc.
Via Business Wire
Personalis to Announce First Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
From Personalis, Inc.
Via Business Wire
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
From Personalis, Inc.
Via Business Wire
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
From Personalis, Inc.
Via Business Wire
Personalis Appoints Christopher Hall as Chief Executive Officer
From Personalis, Inc.
Via Business Wire
Toll Brothers To Rally 25%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Earnings Scheduled For February 23, 2023
Via Benzinga
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
Via Benzinga
Why Personalis Shares Are Trading Higher Today
Via Benzinga
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
From Personalis, Inc.
Via Business Wire
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
From Personalis, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.